Liquidia Q3 net loss $15.8M; YUTREPIA PH-ILD PDUFA Jan 24, 2024

Liquidia Corp

2023-Q3 EPS reported -$0.79 revenue$12,957,000

Net loss $15.8M ($0.24/sh) vs $9.1M ($0.14/sh) in Q3 2022; cash $76.2M vs $93.3M at year-end.
Revenue $3.7M (+15% YoY) from Sandoz treprostinil injection promotion agreement.
R&D spend up 65% to $7.4M on YUTREPIA pre-launch; G&A up 57% to $10.6M on litigation and commercial prep.
PDUFA date for PH-ILD label expansion Jan 24, 2024; final approval delayed to Mar 31, 2024 due to Tyvaso exclusivity.
Oral arguments in '793 patent appeal set for Dec 4, 2023; CAFC ruling could enable final YUTREPIA approval.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Liquidia Corp reported the third quarter ended September 30, 2023 results: revenue $3.7 million.

Period: the third quarter ended September 30, 2023
Revenue: $3.7 million
Result: reported results

Exact text from the filing

for PAH and PH-ILD. Third Quarter 2023 Financial Results Cash totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30, 2022. Revenue related primarily to the promotion agreement

View on SEC.gov

Browse all earnings releases →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-114983

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.